Placeholder Banner

BIO Comments on FDA's Guidance on Consultation Procedures: Foods Derived from New Plant Varieties

February 9, 2017

BIO submitted comments to the Food and Drug Administration (FDA) on its request for input on a public notice, Guidance on Consultation Procedures: Foods Derived from New Plant Varieties.

BIO applauds FDA’s work to develop and enforce a sensible, science-based approach to the regulation of products of agricultural biotechnology. FDA’s consultation process has worked well for nearly 30 years, and BIO members do not consider the current information requests to be unduly burdensome.

However, BIO strongly encourages the FDA to identify mechanisms to better incorporate its experience over time and, where possible, implement more efficient, streamlined review processes for products similar to ones the agency has reviewed in the past as well as products reviewed by the Center for Food Safety and Nutrition (CFSAN) and the Center for Veterinary Medicine (CVM).

Download Full Comments Below
BIO Comments On FDA ICR Final
Read the full comments letter here:
Discover More
We the undersigned Governors would like to draw your attention to an important issue facing U.S. agriculture. Farmer access to new biotechnologies, such as gene editing, is critical to maintaining the security and stability of the rural economy and…
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…